Sections
Title | Starting Page | Number of Pages |
---|
Table of Contents | 2 | 11 |
List of Tables | 11 | 1 |
List of Figures | 12 | 1 |
Introduction | 13 | 1 |
Global Markets Direct Report Coverage | 13 | 1 |
Influenza A Virus, H5N1 Subtype Infections Overview | 14 | 1 |
Therapeutics Development | 15 | 2 |
Pipeline Products for Influenza A Virus, H5N1 Subtype Infections Overview | 15 | 1 |
Pipeline Products for Influenza A Virus, H5N1 Subtype Infections Comparative Analysis | 16 | 1 |
Influenza A Virus, H5N1 Subtype Infections Therapeutics under Development by Companies | 17 | 3 |
Influenza A Virus, H5N1 Subtype Infections Therapeutics under Investigation by Universities/Institutes | 20 | 1 |
Influenza A Virus, H5N1 Subtype Infections Pipeline Products Glance | 21 | 3 |
Late Stage Products | 21 | 1 |
Clinical Stage Products | 22 | 1 |
Early Stage Products | 23 | 1 |
Influenza A Virus, H5N1 Subtype Infections Products under Development by Companies | 24 | 4 |
Influenza A Virus, H5N1 Subtype Infections Products under Investigation by Universities/Institutes | 28 | 1 |
Influenza A Virus, H5N1 Subtype Infections Companies Involved in Therapeutics Development | 29 | 36 |
Akshaya Bio Inc | 29 | 1 |
Altimmune Inc | 30 | 1 |
Antigen Express Inc | 31 | 1 |
Aphios Corp | 32 | 1 |
BioDiem Ltd | 33 | 1 |
BiondVax Pharmaceuticals Ltd | 34 | 1 |
CEL-SCI Corp | 35 | 1 |
Cocrystal Pharma Inc | 36 | 1 |
Emergent BioSolutions Inc | 37 | 1 |
Gemmus Pharma Inc | 38 | 1 |
GlaxoSmithKline Plc | 39 | 1 |
Hemispherx Biopharma Inc | 40 | 1 |
iBio Inc | 41 | 1 |
Inovio Pharmaceuticals Inc | 42 | 1 |
Johnson &Johnson | 43 | 1 |
Kineta Inc | 44 | 1 |
Lakewood-Amedex Inc | 45 | 1 |
Medicago Inc | 46 | 1 |
Medigen Vaccine Biologics Corp. | 47 | 1 |
Microbiotix Inc | 48 | 1 |
NanoBio Corp | 49 | 1 |
Nanotherapeutics Inc | 50 | 1 |
NanoViricides Inc | 51 | 1 |
NewLink Genetics Corp | 52 | 1 |
OPKO Health Inc | 53 | 1 |
PaxVax Inc | 54 | 1 |
PeptiDream Inc | 55 | 1 |
Protein Sciences Corp | 56 | 1 |
Shionogi &Co Ltd | 57 | 1 |
Takeda Pharmaceutical Company Ltd | 58 | 1 |
TechnoVax Inc | 59 | 1 |
TGV-Laboratories | 60 | 1 |
Vaxart Inc | 61 | 1 |
Vaxine Pty Ltd | 62 | 1 |
VaxInnate Corp | 63 | 1 |
Visterra Inc | 64 | 1 |
Influenza A Virus, H5N1 Subtype Infections Therapeutics Assessment | 65 | 10 |
Assessment by Monotherapy Products | 65 | 1 |
Assessment by Combination Products | 66 | 1 |
Assessment by Target | 67 | 2 |
Assessment by Mechanism of Action | 69 | 2 |
Assessment by Route of Administration | 71 | 2 |
Assessment by Molecule Type | 73 | 2 |
Drug Profiles | 75 | 98 |
A-06 Drug Profile | 75 | 1 |
AE-443p Drug Profile | 76 | 1 |
Alferon LDO Drug Profile | 77 | 2 |
APP-0205 Drug Profile | 79 | 1 |
APP-309 Drug Profile | 80 | 1 |
AT-301 Drug Profile | 81 | 1 |
CEL-1000 Drug Profile | 82 | 2 |
CHOS-05 Drug Profile | 84 | 1 |
DPC-005 Drug Profile | 85 | 1 |
FBF-001 Drug Profile | 86 | 1 |
Gamma-Flu Drug Profile | 87 | 1 |
GP-1001 Drug Profile | 88 | 1 |
GP-1002 Drug Profile | 89 | 1 |
GP-1681 Drug Profile | 90 | 2 |
GREFLU/VIE Drug Profile | 92 | 1 |
HAI-05 Drug Profile | 93 | 1 |
HB-36.6 Drug Profile | 94 | 1 |
Influ-nRNA Drug Profile | 95 | 1 |
influenza [strain A/H5N1] (split virion) vaccine Drug Profile | 96 | 1 |
influenza [strain A/H5N1] (virus like particle) vaccine 2 Drug Profile | 97 | 3 |
influenza [strain A/H5N1] vaccine Drug Profile | 100 | 1 |
influenza [strain A/H5N1] vaccine Drug Profile | 101 | 1 |
influenza [strain A/H5N1] vaccine Drug Profile | 102 | 2 |
influenza [strain A/H5N1] vaccine Drug Profile | 104 | 1 |
influenza [strain A/H5N1] vaccine Drug Profile | 105 | 1 |
influenza [strain A/H5N1] vaccine Drug Profile | 106 | 1 |
influenza [strain A/H5N1] vaccine Drug Profile | 107 | 1 |
influenza [strain A/H5N1] vaccine Drug Profile | 108 | 1 |
influenza [strain A/H5N1] vaccine Drug Profile | 109 | 1 |
influenza [strain A/H5N1] vaccine 2 Drug Profile | 110 | 1 |
influenza [strains A/H1N1 + A/H3N2 + A/H5N1] (virus like particle) vaccine Drug Profile | 111 | 1 |
influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine Drug Profile | 112 | 1 |
influenza [strains A/H5N1 + A/H1N1] vaccine Drug Profile | 113 | 1 |
influenza [strains A/H5N1 + A/H7N2 + A/H9N2] (virus like particle) vaccine Drug Profile | 114 | 1 |
influenza vaccine Drug Profile | 115 | 1 |
INO-3510 Drug Profile | 116 | 2 |
JNJ-872 Drug Profile | 118 | 2 |
KD-295 Drug Profile | 120 | 1 |
KIN-1148 Drug Profile | 121 | 1 |
Lalistat Drug Profile | 122 | 1 |
M-001 Drug Profile | 123 | 5 |
MBX-2329 Drug Profile | 128 | 1 |
MBX-2546 Drug Profile | 129 | 1 |
Monoclonal Antibodies to Inhibit Hemagglutinin for Avian Infection and Swine Flu Infection Drug Profile | 130 | 1 |
MV-4 Drug Profile | 131 | 1 |
MVAH-5HA Drug Profile | 132 | 1 |
Nasovax Drug Profile | 133 | 2 |
NVINF-1 Drug Profile | 135 | 4 |
NVINF-2 Drug Profile | 139 | 3 |
OrniFlu Drug Profile | 142 | 1 |
PanBlok Drug Profile | 143 | 3 |
PD-001 Drug Profile | 146 | 1 |
PNSIA-28 Drug Profile | 147 | 1 |
PNSIA-49 Drug Profile | 148 | 1 |
PXVX-0103 Drug Profile | 149 | 1 |
rintatolimod Drug Profile | 150 | 9 |
S-033188 Drug Profile | 159 | 2 |
Small Molecules for Influenza A Virus H1N1 and H5N1 Infections Drug Profile | 161 | 1 |
Small Molecules to Activate Sirtuin for Influenza Drug Profile | 162 | 1 |
Small Molecules to Inhibit PB2 for Influenza Drug Profile | 163 | 1 |
Synthetic Peptides for Influenza, HSV and HIV Infections Drug Profile | 164 | 1 |
Synthetic Peptides for Viral Infections Drug Profile | 165 | 1 |
TVX-003 Drug Profile | 166 | 1 |
VAX-161C Drug Profile | 167 | 1 |
VGX-3400X Drug Profile | 168 | 1 |
VH-244 Drug Profile | 169 | 1 |
VIS-410 Drug Profile | 170 | 3 |
Influenza A Virus, H5N1 Subtype Infections Dormant Projects | 173 | 6 |
Influenza A Virus, H5N1 Subtype Infections Discontinued Products | 179 | 1 |
Influenza A Virus, H5N1 Subtype Infections Product Development Milestones | 180 | 10 |
Featured News &Press Releases | 180 | 1 |
Jun 01, 2016: NanoBio To Present Data Demonstrating Benefit Of Its Intramuscular Nanoemulsion Pandemic Influenza Vaccine | 180 | 1 |
Mar 22, 2016: Kineta to Present New Vaccine Adjuvant Data at the World Vaccine Congress | 181 | 1 |
Sep 30, 2015: BiondVax Initiates a Phase IIb Clinical Trial in Europe for its Universal Flu Vaccine for Pandemic Outbreak | 181 | 1 |
Jun 02, 2015: Visterra Announces Presentation of Data at International Influenza Meeting on the Efficacy of VIS410 for Treatment of a Deadly Strain of Avian Influenza | 182 | 1 |
Mar 23, 2015: Kineta to Present New Vaccine Adjuvant Data at the World Vaccine Congress in Washington D.C. | 182 | 1 |
Oct 29, 2014: BiondVax Receives Approvals for Patent in Europe and Japan for its Universal Flu Vaccine | 183 | 1 |
Mar 24, 2014: Valneva Announces the First Ever Marketing Authorization for a Human Vaccine Produced in the EB66 Cell Line | 183 | 1 |
Feb 17, 2014: BiondVax will Present Clinical Results and the Company's Strategy for Pandemic Preparedness Ahead of Flu Outbreak at the World Health Organization's Key Influenza Meeting | 184 | 1 |
Feb 10, 2014: BiondVax Receives Patent Registration Approval for Multimeric Multiepitope Influenza Vaccines in Hong Kong as well as Allowance of Patent Registration in US for the Company s Universal Flu Vaccine | 184 | 1 |
Jan 21, 2014: BiondVax s universal flu vaccine matches all 6 potentially pandemic flu strains in the world today: H5N1, H5N8, H6N1, H7N 7 , H7N 9 and H10N8 | 185 | 1 |
Oct 03, 2013: BiondVax is a member of the UNISEC consortium awarded a European Commission FP7 grant of 6 million EURO | 186 | 1 |
Sep 09, 2013: Visterra Presents Prophylactic and Therapeutic Efficacy Data of VIS410 Against Multiple Influenza Strains with Pandemic Potential | 186 | 1 |
Aug 25, 2013: Priming with BiondVax s universal influenza vaccine broadens the activity of conventional bird pandemic vaccine against emerging strains | 187 | 1 |
Apr 09, 2013: Medicago And IDRI To Present Positive Interim Phase I Clinical Trial Results Of H5N1 Vaccine At 2013 World Vaccine Congress | 188 | 1 |
Apr 02, 2013: Vivalis Announces Submission Of First New Drug Application For H5N1 Pandemic Influenza Vaccine In Japan | 189 | 1 |
Appendix | 190 | 2 |
Methodology | 190 | 1 |
Coverage | 190 | 1 |
Secondary Research | 190 | 1 |
Primary Research | 190 | 1 |
Expert Panel Validation | 190 | 1 |
Contact Us | 190 | 1 |
Disclaimer | 191 | 1 |